Shares of generic drugmaker Actavis have gone on a huge run lately, which has caught the attention of would-be acquirers. But instead of getting gobbled up, Actavis went on the offense and will buy a spec pharma for $8.5 billion.

In this video, health-care analyst David Williamson discusses the merits of two competing deals for Actavis, one from generic drug company Mylan and another from serial acquirer Valeant. He also talks about why Actavis' purchase of Warner Chilcott worked out for the best for all parties involved.

David Williamson and The Motley Fool have no position in any stocks mentioned. Follow David on Twitter @MotleyDavid. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.